The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

NCT03084250 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis B

Interventions

DRUG: Peginterferon Alfa-2A
DRUG: Adefovir, entecavir,tenofovir, either of them

Sponsor

Shanghai Nanhui Nanhua Hospital